Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the…
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G
Statistically significant 68% (p
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to…
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were…
PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group
EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function –…
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamabFelzartamab, an investigational anti-CD38 monoclonal antibody,…
ECARX Powers Global Launch of the smart #5 Premium Mid-Size SUV
SHANGHAI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, in partnership with AMD, the high performance and adaptive…
Dépôt du projet de note d’information relatif à l’offre publique d’achat visant les actions de la société Esker S.A initiée par Boréal Bidco SAS
Lyon, le 25 octobre 2024 Dans le contexte du projet d’offre publique visant les actions d’Esker SA (le Projet d’OPA), le document PDF téléchargeable ci-après constitue le communiqué dit «…
DTE Energy begins operating its largest solar park, Sauk Solar
Detroit, Oct. 25, 2024 (GLOBE NEWSWIRE) -- DTE Energy (NYSE:DTE), Michigan’s largest producer of and investor in renewable energy, today announced that its largest solar park, Sauk Solar, is now…